{"name":"Getinge AB","slug":"getinge","ticker":"GETI-B","exchange":"Stockholm","domain":"getinge.com","description":"Getinge AB is a publicly traded Swedish medical technology company. The company produces and distributes medical products and equipment for the healthcare and life sciences industries. The company is divided into three business areas: Life Science, Acute Care Therapies, and Surgical Workflows. The group employs approximately 12,000 people worldwide. The CEO of the company is Mattias Perjos, and the chairman of the board is Johan Malmquist. With a sales share of around 40%, the United States is by far the most important market for the company due to significantly higher prices and margins there. China and various Western European countries follow.","hq":"Gothenburg, Sweden","founded":1904,"employees":"~11,000","ceo":"Mattias Perjos","sector":"Medical Devices / Surgical & ICU","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"43.4B","metrics":{"revenue":3500000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Atrium 2 patent cliff ($1.2B at risk)","drug":"Atrium 2","type":"patent_expiry","sentiment":"negative"},{"date":"2027-06-01","label":"Atrium 3 patent cliff ($800M at risk)","drug":"Atrium 3","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-09-28","type":"earnings","headline":"Getinge AB Reports Q3 2023 Earnings","summary":"Getinge AB reported its Q3 2023 earnings, with revenue of SEK 10.3 billion and an operating profit of SEK 1.3 billion.","drugName":"","sentiment":"neutral"},{"date":"2023-06-15","type":"deal","headline":"Getinge AB Acquires ICU Medical","summary":"Getinge AB acquired ICU Medical, a US-based medical device company, for approximately SEK 60 billion.","drugName":"","sentiment":"positive"},{"date":"2022-03-18","type":"regulatory","headline":"Getinge AB Receives FDA Clearance for New Surgical Instrument","summary":"Getinge AB received FDA clearance for its new surgical instrument, which is designed for use in minimally invasive procedures.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTFBtUkd6ZHYzN016ZVJhOTJzMlc3OGFVOFR2bElDTnRxM0E4ZjJDX3JOZmlwOV9qX0RZVVhoT2t4UVBvYjZaYTRZZXFKQ3d3WXVIR2VZdlRWcDc?oc=5","date":"2017-05-27","type":"pipeline","source":"Yahoo Finance Australia","summary":"Getinge AB (publ) (GETI-B.ST) stock price, news, quote and history - Yahoo Finance Australia","headline":"Getinge AB (publ) (GETI-B.ST) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Atrium 2","drugSlug":"atrium-2","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Atrium 3","drugSlug":"atrium-3","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":800000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Stryker","Medtronic","Becton Dickinson"],"therapeuticFocus":["Surgical Instruments","ICU Equipment"],"financials":null,"yahoo":null}